Privacy Policy Site Map Medical Website Design & Marketing by Etna Interactive Copyright 2026 Christopher J
However, GLP-/GIP dual agonists have been proved to be orally effective in animal experiments, and its state in plasma is more stable than GLP-1RA [141], and this oral administration method has gradually been applied to the clinic [142]
Others have a later peak around weeks 9-10
The LEADER trial enrolled patients with T2DM and high cardiovascular risk, defined as established CVD (81%) or age 60 years with at least one risk factor, and showed that liraglutide significantly reduced the incidence of 3-point major adverse cardiovascular events (MACE) (i.e., CV death, non-fatal myocardial infarction, non-fatal stroke) by 13% compared to placebo (HR 0.87
As a result, they improve blood sugar control after meals
doi: 10.1111/jnc.13837